UCB Moves Up Myasthenia Gravis Pipeline With Rozanolixizumab Win

Slips Into Second Place Behind Argenx's Efgartigimod

 
• By Kevin Grogan
UCB flag
• Source: UCB

More from Rare Diseases

More from Scrip